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value (NPV) and overall diagnostic accuracy) were calculated at the patient, vessel 
and segment level. RESULTS: This systematic review included 28 studies. The base 
case meta-analysis at the patient-level indicated a sensitivity of 98.2%, speciﬁ city of 
81.6%, PPV of 88.9%, NPV of 96.8%, and diagnostic accuracy of 91.6%. In all 
vessels, the pooled sensitivity was 95.0%, speciﬁ city 85.2%, PPV 69.4%, NPV 97.9%, 
and diagnostic accuracy 87.7%. At the individual artery level, overall diagnostic 
accuracy appeared to be slightly higher in the left and right coronary artery and slightly 
lower in the left anterior descending and circumﬂ ex artery. In all segments, the sensitiv-
ity was 91.1%, speciﬁ city 94.3%, PPV 65.7%, NPV 98.9%, and overall diagnostic 
accuracy 94.0%. CONCLUSIONS: The high sensitivity observed in this update indi-
cates that CTA can effectively identify the majority of patients with signiﬁ cant coro-
nary artery stenosis. The high NPV at the patient, vessel and segment level establishes 
CTA as an effective noninvasive alternative to ICA for the exclusion of stenosis. 
PODIUM SESSION II: DIABETES STUDIES
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EVALUATING THE COST-EFFECTIVENESS OF THERAPY CONVERSION 
FROM BASAL INSULIN TO BIPHASIC INSULIN ASPART 30/70 IN 
PATIENTS WITH TYPE 2 DIABETES IN CHINA: A MODELING STUDY OF 
LONG-TERM COSTS AND HEALTH OUTCOMES
Chang J1, Sun F1, Li H2
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OBJECTIVES: To evaluate the long-term cost-effectiveness of switching from basal 
insulin to biphasic insulin aspart 30 (BIAsp30) in patients with type 2 diabetes (T2D) 
in China. METHODS: A published and validated computer simulation model of 
diabetes (CORE Diabetes Model) was used to project long-term (30 years) of health 
and economic outcomes. Simulated cohorts and treatment effects were derived from 
a 16-week, multi-center, and single-arm trial-NCT00669864 which investigated the 
efﬁ cacy and safety of BIAsp30 ± Metformin in T2D patients inadequately controlled 
with basal insulin. Two subgroups of basal insulin treatment were categorized as 
insulin glargine (IGla) ± Metformin and neutral protamine hagedorn (NPH) insulin ± 
Metformin. The market retail prices of medications were calculated to estimate treat-
ment costs. The diabetes management and complications costs were obtained from 
Chinese published data. An annual discounting rate of 3% was used for both costs 
and health outcomes. One-way sensitivities analysis was performed. RESULTS: 
Therapy conversion to BIAsp30 was projected to improve life expectancy signiﬁ cantly 
in comparison with IGla (0.347 ± 0.245 years), and NPH (0.452 ± 0.242 years). 
Transfer to BIAsp30 was associated with improvements in 0.327 quality-adjusted 
life-years (QALYs) over IGla, and 0.393 QALYs over NPH. Therapy conversion to 
BIAsp30 reduced medical costs by Chinese Yuan (CNY) 46,540 per patient compared 
to IGla. However, it increased CNY 19,525 compared to NPH and was associated 
with an incremental cost-effectiveness ratio of CNY 49,730 per QALY gained. CON-
CLUSIONS: Therapy conversion from basal insulin to BIAsp30 in T2D patients in 
China was associated with improvements in life expectancy and QALYs. Transfer to 
BIAsp30 was cost-saving treatment strategy in T2D patients managed with IGla, and 
would be considered cost-effective in T2D patients managed with NPH, given a 
willingness-to-pay threshold of CNY 75,375 per QALY (three times GDP per capita 
in 2009) gained in China. 
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TRANSLATION AND VALIDATION OF MICHIGAN DIABETES 
KNOWLEDGE SCALE INTO MALAYSIAN VERSION
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OBJECTIVES: To translate the Michigan Diabetes Knowledge Scale (MDKT) into the 
Malaysian language, and to examine the psychometric properties of the Malaysian 
version of the MDKT among patients with type 2 diabetes, including its validity and 
reliability. METHODS: After obtaining permission, a standard “forward-backward” 
translation procedure was used to create the Malaysian version of the MDKT from 
the original English version. A convenience sample of 307 outpatients with type 2 
diabetes was identiﬁ ed between May and October, 2009. All data were collected from 
the Penang General Hospital, Penang, Malaysia. Instruments consisted of the Malay-
sian version of MDKT and a socio-demographic questionnaire. Medical records were 
reviewed for hemoglobin A1C (HbA1C) levels and other clinical data. Reliability was 
tested for internal consistency using Cronbach’s α coefﬁ cient. Validity was conﬁ rmed 
using known group validity. RESULTS: Employing the recommended scoring method, 
the mean ± SD of MDKT scores was 7.88 ± 3.01. Good internal consistency was 
found, (`’s α = 0.702), the test–retest reliability value by using Spearman’s rank cor-
relation was 0.894 (P < 0.001). For known group validity, a signiﬁ cant relationship 
between MDKT categories and HbA1c categories (×2 = 21.626; P ≥ 0.001) was found. 
CONCLUSIONS: The MDKT can be used for diabetes knowledge assessment in 
diabetes. The ﬁ ndings of this validation study indicate that the Malaysian version of 
the MDKT is a reliable and valid measure of medication adherence which can now 
be used in clinical and research practice. 
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LIFETIME CLINICAL PROJECTIONS FOR OVERWEIGHT OR OBESE 
SUBJECTS WITH IMPAIRED GLUCOSE INTOLERANCE BASED ON THE 
LONG TERM RESULTS OF THE DIABETES PREVENTION PROGRAM AND 
DIABETES PREVENTION PROGRAM OUTCOMES STUDY
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OBJECTIVES: Metformin and intensive lifestyle interventions (ILI) were shown to 
reduce incidence of type 2 diabetes (T2D) versus standard care in overweight or obese 
subjects with impaired glucose tolerance (IGT) in the Diabetes Prevention Program 
(DPP) trial and Diabetes Prevention Program Outcomes Study (DPPOS), a total fol-
low-up of 10 years. Our aim was to project the lifetime clinical outcomes to be 
expected from T2D prevention in high-risk subjects treated with standard care, met-
formin or ILI, based on the results from the DPP + DPPOS. METHODS: A semi-
Markov, second-order Monte Carlo model was developed to project the 10-year 
clinical results of the DPP + DPPOS to patient lifetimes. Speciﬁ cally, we calculated 
years free of T2D, cumulative incidences of T2D, and nondiscounted life expectancies 
in subjects who were initiated on diabetes prevention regimens based on metformin, 
ILI or standard care. Four health states were modeled: normoglycemia (NG); IGT; 
T2D and dead. Subjects started in IGT and progressed to T2D or NG, at rates depen-
dent on the treatment received. State-speciﬁ c mortality rates for NG, IGT or T2D were 
used. Univariate and probabilistic sensitivity analyses were performed. RESULTS: For 
standard care, metformin or ILI, mean (standard deviation) number of years free of 
T2D were 9.47 (0.08), 11.98 (0.09), 15.17 (0.11) years respectively. Cumulative 
incidences of T2D were 89.7% (0.2), 83.7% (0.2) and 73.4% (0.3%) for standard 
care, metformin or ILI respectively. Mean life expectancies from baseline age of 50 
years were 27.64 (0.14), 27.95 (0.12), 28.33 (0.11) years for standard care, metformin 
or ILI respectively. Results were most sensitive to the relative risk reduction in the 
incidence of T2D and relative risks of mortality in the T2D state versus IGT state. 
CONCLUSIONS: Substantial improvements in lifetime clinical outcomes can be 
expected in high risk subjects treated with metformin or ILI to delay or prevent the 
onset of T2D. 
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OBJECTIVES: The cost-effectiveness of adding thiazolidinediones (TZDs), rosigli-
tazone or pioglitazone, to metformin in treating type-2 diabetes mellitus was assessed 
from a Taiwanese national health insurance perspective. METHODS: This analysis 
was based on patient-level data extracted from the 2000–2005 Taiwan’s National 
Health Insurance (NHI) databases. Type 2 diabetic patients who had their ﬁ rst ambu-
latory visits with a diagnosis of diabetes mellitus and had received consecutive met-
formin treatments between 2001 and 2005 were identiﬁ ed. Clinical effectiveness, a 
proxy of glycemic control (time to insulin dependence), and direct medical cost also 
were estimated from the NHI databases. Incremental cost-effectiveness ratio (ICER) 
was calculated and expressed as cost per delayed year to insulin dependence. 
RESULTS: The use of TZDs as add-on therapy compared non-TZDs add-on therapy 
was associated with a delay in time to insulin dependence, rosiglitazone was associated 
with an additional 151 days (0.41 years) and pioglitazone was associated with an 
additional 101 days (0.28 years) of delay in insulin dependence. During the follow-up 
period, total mean medical costs were higher in patients who received an add-on 
rosiglitazone (New Taiwan dollars (NT) 153,162) or pioglitazone (NT 139,931) 
compared to add-on non-TZDs (NT 113,492) and the additional medical costs were 
driven primarily by diabetic medication cost and outpatient visit costs. Combining the 
cost and effectiveness results, the ICER showed that the additional total medical costs 
of add-on rosiglitazone or pioglitazone were comparable, with ICERs of 95,874 and 
95,485 NT dollars per year delay in insulin dependence, respectively. CONCLU-
SIONS: This analysis suggests that add-on rosiglitazone or pioglitazone improves 
glycemic control but also increases direct medical costs compared with add-on non-
TZDs when used in type-2 diabetic patients. In terms of the incremental medical costs 
associated with these clinical beneﬁ ts, add-on rosiglitazone or pioglitazone are similar 
in the National Health Insurance system in Taiwan. 
PODIUM SESSION II: DATABASE STUDIES
DS1
ESTIMATING ADHERENCE AND PERSISTENCY OF ANTIDEPRESSANTS 
USING THE KOREA NATIONAL HEALTH INSURANCE CLAIMS 
DATABASE
Jung SY, Song H, Shin S, Shin E, Park J1, Ahn J
National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea
OBJECTIVES: To investigate adherence and persistence of antidepressants (ADs) 
among the patients with depression in Korea. METHODS: Using the Korean Health 
Insurance Review & Assessment Service (HIRA) claims database (2006–2008), 
patients aged 18–84 with at least one inpatient or two outpatient diagnoses of depres-
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sion (ICD 10 = F06.3, F31.3, F31.4, F32, F33, F34.1, F38.1, F41.2) within 1 year 
before the ﬁ rst observed prescription of ADs between January 2007 to June 2008 
(Index period: 18 months) were identiﬁ ed. ADs were categorized as tricyclic antide-
pressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and new antidepres-
sants (NADs; SNRIs and others). For each AD category, adherence by Medication 
possession ratio (MPR) of 180 days post-index period and persistence by duration of 
uninterrupted therapy (DUR) with a 14-day permissible gap were estimated. Addi-
tional subgroup analyses by non-adherence (MPR < 75%) and by early dropout (DUR 
< 90 days) were included. Multivariable logistic regression analysis was performed to 
further investigate the relationship between AD categories and adherence (persistence). 
RESULTS: Of 318,490 patients satisﬁ ed the selection criteria, mean MPR was 0.52 
(SD = 0.34) and mean duration of uninterrupted therapy of were 118.08 days (SD = 
67.67). Non-adherence proportion was 65.9%, and early dropout rate was 36.7%. 
Patients prescribed by psychiatrists (N = 208,791) showed signiﬁ cantly higher MPR 
(0.54 vs. 0.40; P < 0.001) and persistence (125.43 vs. 102.67; P < 0.001). When 
adjusted for age, gender, pre-/post- inpatient or outpatient visits, Chalson’s comorbid-
ity index, hypertension, and hyperlipidemia, with TCA as reference, patients pre-
scribed NADs (aOR = 1.75 [1.70–1.80]) and SSRIs (aOR = 1.56 [1.52–1.60]) were 
associated higher adherence, whereas SSRIs were associated higher (aOR = 1.03 
[1.01–1.05]) but NADs were associated lower (aOR = 0.93 [0.91–0.96]) persistence. 
CONCLUSIONS: Contrary to the previous literature, Korean adherence and persis-
tence of ADs were not signiﬁ cantly lower than the United States or Europe. In addi-
tion, NADs showed an advantage in terms of adherence and SSRIs had an edge in 
terms of persistence. 
DS2
TREND OF ANTIHYPERTENSIVE MEDICATIONS AND RISK OF STROKE 
AMONG HYPERTENSIVE PATIENTS IN TAIWAN: BASED ON THE NHI 
DATABASE
Chu NF
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OBJECTIVES: Hypertension (HTN) is an important and prevalent risk factor for 
cardiovascular diseases. In Taiwan, the prevalence of hypertension is around 21.4% 
and only about 40% patients with acceptable range of blood pressure control. The 
purpose of this study is to evaluate the trend of antihypertensive medications and also 
examine the risk of stroke among these HTN patients from 2001 to 2004 in Taiwan. 
METHODS: Based on the National Health Insurance (NHI) database, there are 
1,931,436 patients with ICD-9 coding of hypertension, we randomly selected 10% 
hypertension outpatients (194,547 subjects) from the NHI claim database, after 
excluded those visited less than three times or without anti-HTN medication, 135,660 
patients in the ﬁ nally analyses. These subjects follow their anti-HTN medications and 
occurrence of stroke for a 4-year period. RESULTS: Among these patients, 27.6% 
used only one medication and 37.0% with three or more medications for HTN. There 
are 9530 (4402 males and 5128 females) patients had both drug information on 2001 
and 2004. The prevalence of stoke was 7.3% in 2001 and increased to 13.6% in 2004. 
The average out-patient medical costs for hypertension were increased from 
NT$15,778.7 to 19,712.1 dollars (at an exchange rate of 32 NT$ to 1 US$) from 
2001 to 2004. Using Cox proportion hazard model, gender (male) and age were 
important factors to predict the occurrence of stroke. Comparing with beta-blocker, 
diuretics had higher relative risk for stoke but the risk was attenuate after adjusted 
for other confounders (HR = 1.3, 95% CI 0.7−2.6). CONCLUSIONS: From this 
study, the out-patient medical costs for hypertension were increased from 2001 to 
2004 in Taiwan. However, the occurrence of stroke among hypertensive patients was 
also increased during this period. There was no signiﬁ cant protective effect for stroke 
among hypertensive patients using different anti-HTN medications. Further studies 
may be indicated to evaluate the cost-effectiveness of different medications on 
hypertensive-related disorders. 
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BACKGROUND: Several statistical methods have been applied to detect signals in 
spontaneous reporting databases. The Thailand Food and Drug Administration (Thai 
FDA) uses the reporting odds ratio (ROR) method for signal detection because of its 
ease of implementation and interpretation. The performance of different methods 
needs to be explored to determine need for modiﬁ cations to the Thai FDA signal 
detection system. OBJECTIVES: To examine the concordance between the ROR and 
the Bayesian Conﬁ dence Propagation Neural Network (BCPNN) methods in identify-
ing adverse drug reaction (ADR) signals using the Thai FDA database. METHODS: 
The two methods were retrospectively applied to identify ADRs reported with anti-
retroviral (ARV) drugs using the dataset from 1990 to 2006. The criteria of lower 
limit of 95% conﬁ dence interval of ROR >1, 3 or more cases; and information com-
ponent (IC) two standard deviations >0, were used to identify signals for ROR and 
BCPNN, respectively. The sensitivity, speciﬁ city and agreement of timing of signal 
detection were measured for the concordance of the ROR in respect to the BCPNN. 
RESULTS: Using the BCPNN as a reference method, the ROR has high sensitivity 
and speciﬁ city. For the agreement of timing of signal detection between the ROR and 
the BCPNN, signals detected by both methods were in agreement on the ﬁ rst time of 
signal detection for 76.92%. CONCLUSIONS: ROR and BCPNN are comparable in 
identify signals of potential ADRs. Comparisons using other drug classes will provide 
additional insight into the performance of these two methods. 
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HERBAL PRODUCTS SAFETY: AN APPLICATION OF HEALTH PRODUCT 
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OBJECTIVES: The use of herbal products continues to expand rapidly across the 
world. The concerns of safety of herbal products have been raised. Health Product 
Vigilance Center (HPVC) database (Thai Vigibase) is the national existing health 
products surveillance system which can be used to detect signal of adverse events (AEs) 
in patients receiving herbal products. This study aims to describe and characterize 
reported AEs in patients receiving herbal products in Thailand. METHODS: Thai 
Vigibase data from February 2000 to December 2008 involving AEs of reported herbal 
products were included. The database contained patients’ demographic, AEs associ-
ated with herbal products, seriousness, causality and quality of reports. Descriptive 
statistics were used for data analyses. RESULTS: A total of 593 reports with 1868 
AEs were reported during the study period. The age range of reported cases was 1 to 
86 years (mean, 47 years). Female patients were frequently reported (72%). Reports 
involving turmeric were most frequently reported. Gastro-intestinal problems were the 
most common clinical outcomes among herbal products associated with adverse 
events. Severe adverse events such as Stevens Johnson syndrome, anaphylactic shock 
and exfoliative dermatitis were also found. CONCLUSIONS: HPVC database is a 
potentially effective tool for herbal adverse events monitoring. Encouraging reporting 
can contribute to improve awareness among health personnel and patients about the 
beneﬁ t-harm proﬁ le of the herbal products. 
PODIUM SESSION II: DRUG USE STUDIES
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THE IMPACTS OF ABUSE OF ANTIBIOTIC THERAPIES IN CHINA
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OBJECTIVES: In the 1980s, China launched market-oriented reforms. Public hospi-
tals were encouraged to make their own incomes with the aim of mobilizing medical 
workers and improving hospital efﬁ ciency. Less government funding resulted in deﬁ -
cits for public health institutions, which forced hospitals to generate their own revenue 
by aggressively selling drugs, especially antibiotics. This study was designed to evaluate 
the impact of inappropriate antibiotic use on inpatients’ cost during the hospitaliza-
tion. METHODS: One thousand cases with antibiotic treatment from 10 hospitals of 
ﬁ ve provinces in China in 2006. We created multivariate linear regression model for 
hospital cost and logistic regression model for rationality evaluation of antibiotic use. 
RESULTS: Finally we collected 964 valid cases. Rate of inappropriate antibiotic use 
was 58.4%. Costs of inpatients with inappropriate antibiotic use was as 2.75 times 
as the ones with appropriate use (P < 0.001). Risk factors included antibiotic prophy-
laxis (OR = 2.929), operations (OR = 2.44), long hospital stay (OR = 1.021 for every 
prolonged day) and regional factors. Protection factor was in tertiary hospital (OR = 
0.510). CONCLUSIONS: This study concluded that inappropriate antibiotic use 
contributes to inpatients’ high cost. Efforts to control misuse of antibiotic should be 
pursued. 
DU2
THE UTILIZATION OF PROPHYLACTIC ANTITHROMBOTIC AGENTS 
AFTER MAJOR ORTHOPEDIC SURGERIES—A POPULATION-BASED 
STUDY IN TAIWAN
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OBJECTIVES: Antithrombotic agents have been recommended to prevent venous 
thromboembolism (VTE) after major orthopedic surgeries, yet neither effectiveness 
evidence nor guidance for prophylactic antithrombotic agents is available in Taiwan. 
This study aims to evaluate current utilization of prophylactic antithrombotic agents 
after total hip and knee replacement (THR/TKR). METHODS: This retrospective 
cohort study used a Taiwanese National Health Insurance dataset including 1,000,000 
beneﬁ ciaries randomly sampled in 2005 from nationwide population and followed 
longitudinally from 1995 to 2008. Adults hospitalized for THR or TKR were identi-
ﬁ ed by procedure codes from April 2003 to June 2008. Patients with VTE, bleeding 
events, or antithrombotic prescriptions within 90 days preadmission were excluded. 
Eligible patients’ characteristics, medication during operation, and antithrombotic 
prescription up to 30 days post-admission were collected, presented in descriptive 
statistics, and stratiﬁ ed by different operations. RESULTS: Of all, 1026 THR (41.03% 
women) and 2401 TKR (75.51% women) were identiﬁ ed, with mean age of 56.36 ± 
